Citadel Advisors’s Imago BioSciences, Inc. Common stock IMGO Stock Holding History

Citadel Advisors’s Portfolio IMGO Stock Details IMGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-97,340	Closed	-$3.5M	–	16214
2022 Q4	$3.5M	Sell	97,340 -2,367,410	-96%	-$59.2M	﹤0.01%	4499
2022 Q3	$37.1M	Sell	2,464,750 -52,291	-2%	-$848K	0.01%	1300
2022 Q2	$33.7M	Buy	2,517,041 +18,620	+0.7%	+$296K	0.01%	1371
2022 Q1	$48.1M	Buy	2,498,421 +45,495	+2%	+$944K	0.01%	1151
2021 Q4	$57.3M	Buy	2,452,926 +410,487	+20%	+$9.5M	0.01%	1062
2021 Q3	$40.1M	Buy	+2,042,439	New	+$43.8M	0.01%	1298

Citadel Advisors's IMGO Position: Q1 2023 in Review

Citadel Advisors sold out of Imago BioSciences, Inc. Common stock (IMGO) in Q1 2023, closing a stake of 97,340 shares — an estimated $3.5M sold.

Citadel Advisors first reported a position in IMGO in Q3 2021 and held it in 6 quarters. The position peaked at $57.3M in Q4 2021. 0 funds tracked by Wall St. Rank hold IMGO as of Q1 2023.

Citadel Advisors reported no remaining Imago BioSciences, Inc. Common stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 97,340 Imago BioSciences, Inc. Common stock shares in Q1 2023, an estimated $3.5M.
Citadel Advisors first reported a position in Imago BioSciences, Inc. Common stock in Q3 2021 and held it in 6 quarters.
Citadel Advisors's Imago BioSciences, Inc. Common stock position peaked at $57.3M in Q4 2021.
0 funds tracked by Wall St. Rank held Imago BioSciences, Inc. Common stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.